<div id="readability-page-1"><div>By Megan Cheah Shares of CSPC Pharmaceutical Group fell sharply after the Chinese company inked a multibillion-dollar deal with pharmaceutical giant AstraZeneca for its long-acting obesity drug. The Hong Kong-listed stock dropped as much as 13% before closing 10% lower at 9.60 Hong Kong dollars, equivalent to US$1.23. The decline was its biggest daily percentage loss in nearly a year. CSPC said earlier Friday that it entered an obesity drug agreement with AstraZeneca that would give the U.K.-based pharmaceutical company rights outside China to its clinical-ready long-acting obesity asset and three other preclinical assets. The Chinese company will receive US$1.2 billion upfront and be eligible for up to US$17.3 billion in development and sales milestone payments. Analysts at Macquarie Capital viewed Friday's drop as profit-taking after what they said was CSPC's largest outlicensing deal. The deal cements CSPC's status as one of China's most innovative biopharmaceutical companies, alongside peer Hengrui Pharmaceuticals, at a time when large Chinese pharmaceutical companies are pivoting toward innovation, the analysts said. The new agreement also builds on a previous deal with AstraZeneca, which granted the British company global rights to a preclinical inhibitor for a US$100 million upfront payment in 2024, the analysts said. CSPC's research and development efforts are &#34;clearly bearing fruit,&#34; they said. Friday's share-price decline came after the stock gained 26% this year and could be an entry opportunity for investors, Macquarie Capital said, reiterating its outperform rating and HK$12.40 target price. Write to Megan Cheah at megan.cheah@wsj.com (END) Dow Jones Newswires01-30-26 0454ET</div></div>

石藥集團

石藥集團的股價在與阿斯利康達成一項數十億美元的肥胖藥物交易後下跌了 10%，創下近一年來最大的單日跌幅。根據分析師的説法，股價在獲利了結中下跌至 9.60 港元（1.23 美元）。石藥集團將獲得 12 億美元的預付款，並可能在里程碑付款中賺取高達 173 億美元。儘管股價下跌，分析師們仍將其視為潛在的買入機會，維持 “跑贏大盤” 的評級，目標價為 12.40 港元

石藥集團在與阿斯利康達成協議後，股價因可能的獲利回吐而下跌